FOXO4-DRI Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about FOXO4-DRI dosing — protocols, safety, and where to buy.
Dose Range
5 mg/kg IV infusion (research protocol, highly experimental)
Dosage Calculator
Calculate exact dosing for FOXO4-DRI.
Dosing Protocols
A defensible beginner approach to senolytic therapy does not start with FOXO4-DRI, because FOXO4-DRI is a research peptide with zero human clinical data and research-peptide supply with significant quality variability. A rational beginner senolytic protocol starts with the most evidence-supported and lowest-risk options. Fisetin, a flavonoid found in strawberries and available as a dietary supplement, has senolytic activity demonstrated in preclinical studies and has been tested in early human trials (Yousefzadeh et al., 2018). Fisetin dosing in human senolytic protocols is typically 20 mg/kg daily for 2-3 consecutive days, repeated monthly or quarterly. At this dose fisetin is generally well-tolerated with mild gastrointestinal effects being the most common adverse report. The quercetin-dasatinib combination has more robust clinical evidence, including small human trials in diabetic kidney disease and idiopathic pulmonary fibrosis showing reductions in senescence markers and modest clinical benefits (Justice et al., 2019; Hickson et al., 2019). Dasatinib requires a prescription (it is approved for chronic myeloid leukemia) and should only be used under physician supervision because of off-target effects and drug-drug interactions. These two options — fisetin alone, or physician-supervised dasatinib plus quercetin — are the evidence-based beginner senolytic choices in April 2026. FOXO4-DRI does not belong in a beginner senolytic protocol. If someone has used fisetin cycles without significant adverse effects and wants to experiment with FOXO4-DRI, the beginner approach is conservative: low dose, short cycle, careful monitoring. A typical beginner FOXO4-DRI dose range from self-report communities is 2-5 mg per dose, administered subcutaneously once daily for 3-5 consecutive days, with 2-6 month intervals before any repeat cycle. These doses are extrapolated from rodent studies and vendor recommendations, not from human PK data. The subcutaneous injection is the most common route for self-experimenters; intravenous administration carries higher acute risk and greater technical demands and is not appropriate for beginners. The timing of the 3-5 day dosing window is typically chosen to accommodate the subjective response many users report (flu-like symptoms during and immediately after the dosing window, resolving over 7-14 days). Monitoring during a beginner FOXO4-DRI cycle should include: comprehensive metabolic panel, CBC, and liver function tests before the cycle and 2-4 weeks after; baseline measurement of any condition-specific markers (eGFR for kidney function, HbA1c for metabolic health, etc.); subjective tracking of fatigue, mood, exercise capacity, and any systemic symptoms during and after the cycle. The subjective flu-like response to senolytic dosing is interesting because it may reflect actual senescent cell clearance (release of SASP cytokines and cellular contents into circulation during the kill phase) or may reflect pyrogen contamination in research-chemical supply (endotoxin contamination from manufacturing). Distinguishing between these is difficult without analytical testing of the specific batch being used, and the indistinguishability is one reason high-quality vendor selection matters. Expectations for beginner FOXO4-DRI cycles should be modest. Preclinical data suggest senolytic clearance produces benefits on tissue function and inflammation markers that may not be subjectively obvious after a single cycle. Users who dose once and evaluate based on how they feel the following week are unlikely to have useful data. Users who track objective markers (inflammatory markers like hs-CRP, kidney function markers, HbA1c, body composition, strength) over multiple cycles and year-over-year comparisons are more likely to generate meaningful personal information about whether the intervention is producing measurable changes. The beginner protocol ends with a clear decision framework: if the cycle produces unacceptable adverse effects, cease and do not continue; if the cycle produces no detectable benefits on objective markers across 2-3 cycles, reconsider whether continued use is justified; if the cycle produces clear subjective and objective benefits, cautious continuation is reasonable with ongoing monitoring.
Intermediate FOXO4-DRI users have completed multiple beginner cycles without significant adverse effects, have established confidence in their vendor supply, and are considering more intensive senolytic protocols. An intermediate approach typically involves 5-10 mg per dose subcutaneously for 3-7 consecutive days, repeated every 3-6 months. The higher dose and longer cycle are intended to produce more complete senescent cell clearance on the assumption that a single lower-dose cycle may not eliminate all senescent cells in target tissues. This assumption has not been validated in humans and rests on inference from animal studies. Intermediate users often combine FOXO4-DRI with other senolytics in alternating or concurrent patterns. Fisetin cycles (20 mg/kg for 2-3 days) might be run 2-3 times between FOXO4-DRI cycles, on the theory that different senolytics clear different subsets of senescent cells and coverage benefits from rotation. Dasatinib-quercetin cycles under physician supervision add another senolytic option with distinct selectivity. Stacking multiple senolytics on the same day or within the same week compounds unknown risks and is not recommended even at the intermediate stage. Route of administration for intermediate users is still typically subcutaneous, which is the safer choice for self-administration. Some users experiment with intravenous FOXO4-DRI on the theory that IV delivery produces higher peak concentrations and more rapid tissue distribution, but this is not supported by any clinical data and carries the additional risks of IV access (infection, thrombosis, vascular injury). Self-administered IV peptides are not a defensible practice outside of professional medical supervision with proper aseptic technique, and even then the marginal benefit over SC administration is not established. Intermediate monitoring should be more extensive than beginner monitoring. Pre-cycle and post-cycle labs (2-4 weeks after completing the dosing window) should include: comprehensive metabolic panel; CBC with differential; liver function tests; thyroid panel; lipid panel with ApoB and Lp(a); fasting glucose and HbA1c; inflammatory markers (hs-CRP, fibrinogen, possibly IL-6 if available); condition-specific markers (eGFR, 24-hour urine protein if kidney disease; echocardiogram markers if cardiovascular; specific tumor markers if cancer surveillance is relevant). Trending these markers across multiple cycles provides data on whether the protocol is producing consistent effects or drift. For users with access to more advanced testing, measurement of senescence markers in circulating cells (p16 expression in peripheral blood lymphocytes, senescence-associated miRNAs) is offered by some specialty labs and may provide more direct evidence of senolytic effect. These assays are expensive, not standardized, and their clinical interpretation is not fully established, but they represent the state of the art in noninvasive senescence monitoring and may be worth running at baseline and after 2-3 cycles. Imaging assessments (DEXA for body composition, coronary calcium score, carotid intima-media thickness, bone density) provide complementary data on whether multi-year senolytic protocols are producing measurable phenotypic changes. These imaging studies are not specific to senolytic response but can detect broad changes in tissue composition and cardiovascular risk. Intermediate users should also consider their broader protocol context. Senolytic therapy is meant to complement, not replace, validated interventions that reduce senescent cell accumulation: adequate exercise (particularly resistance training and moderate-intensity aerobic exercise), caloric discipline and weight management, sleep sufficiency, stress management, smoking avoidance, and management of cardiometabolic risk factors. Adding periodic FOXO4-DRI to a lifestyle that includes regular exercise and metabolic health maintenance is a different proposition than adding FOXO4-DRI to a sedentary diet-driven lifestyle; the baseline senescent cell burden and likely senolytic response differ. Intermediate users should also maintain clinical infrastructure: a physician who knows about the protocol, who can order labs and interpret results, who can evaluate any adverse events, and who can provide input on dose or schedule adjustments. Finding a physician with expertise in senolytic pharmacology and longevity medicine is harder than finding one willing to accept payment, and is worth the effort. Cost at the intermediate stage is meaningful. Research-chemical FOXO4-DRI at typical vendor prices runs $150-$400 per 10 mg vial depending on source and quantity. A 7-day cycle at 10 mg daily uses 70 mg of peptide, costing $1,000-$2,800 per cycle at these prices. Cycles 2-4 times per year add up to $4,000-$12,000 annually just for the peptide, plus additional costs for other stacked compounds, labs, and clinical consultations. This expenditure should be evaluated against the evidence that the intervention is producing benefit — if objective markers are not improving across multiple cycles, the financial commitment is probably displacing resources that could go to validated health investments (high-quality food, training, preventive healthcare).
Advanced FOXO4-DRI protocols are used by experienced self-experimenters who have completed multiple intermediate cycles, have robust clinical monitoring, and are integrating senolytic therapy into comprehensive longevity protocols. Advanced dosing can involve 10-15 mg per dose subcutaneously for 5-10 consecutive days per cycle, with cycles every 2-4 months. There is no clinical evidence that higher doses or more frequent cycles produce better outcomes, and the advanced dose ranges primarily increase cumulative exposure and cost without documented additional benefit. The advanced protocol question is less about dose escalation and more about integration with a sophisticated longevity stack: rapamycin (if prescribed off-label for mTOR modulation), metformin (if indicated for glucose control or prescribed off-label for longevity), NAD+ precursors (NR or NMN at evidence-based doses), multiple senolytics rotated (fisetin, dasatinib-quercetin under physician supervision, FOXO4-DRI pulses), mitochondrial support (L-Carnitine, coenzyme Q10, Methylene Blue), epigenetic modulators (methyl donor support, 5-Amino-1MQ for NNMT inhibition), telomere support (Epithalon), tissue repair (BPC-157, TB-500, GHK-Cu), cytoprotection (Humanin, Thymosin Alpha-1), GH/IGF-1 axis support (CJC-1295, Ipamorelin), metabolic support (GLP-1 agonists if indicated). These comprehensive stacks represent the cutting edge of longevity self-experimentation and have essentially no clinical validation for the combinations. Attribution of effects to any specific component is impossible in practice. Users accept attribution loss in exchange for perceived comprehensive coverage of aging mechanisms. Monitoring at the advanced stage should be extensive. Quarterly comprehensive labs: CMP, CBC with differential, LFTs, lipid panel with ApoB and Lp(a), HbA1c and fasting insulin, IGF-1, thyroid panel, homocysteine, hs-CRP, vitamin D, B12, folate, ferritin, testosterone/estradiol as appropriate, and any condition-specific markers. Specialty testing every 6-12 months: circulating senescent cell markers, detailed lipid subparticles if coronary risk is relevant, inflammatory cytokine panels, biological age testing (DNA methylation clocks like GrimAge, PhenoAge). Annual comprehensive imaging: coronary calcium score or CT angiography (for users over 40), carotid ultrasound, DEXA for body composition, bone density, abdominal ultrasound, possibly full-body MRI for cancer surveillance. Age-appropriate cancer screening on standard schedules (colonoscopy, mammography or prostate testing, skin check, etc.). Functional assessments: grip strength, VO2max testing, gait speed, timed up-and-go, balance testing — these functional markers are relevant for sarcopenia and frailty monitoring. Cognitive testing if the protocol is oriented toward cognitive longevity. Blood pressure, heart rate variability, and other continuous monitors via consumer wearables provide daily-granularity data that supplements periodic labs. The purpose of this monitoring intensity is to detect subclinical abnormalities early and to provide data for protocol adjustment. If the protocol is working, the markers should show stable or improving trends over years. If markers drift in concerning directions, the protocol needs revision or the contribution of specific components needs to be evaluated. Advanced users should develop clear decision criteria for protocol adjustment: thresholds for stopping specific components, thresholds for adding new interventions, thresholds for escalating clinical involvement. These pre-committed criteria make it easier to make rational decisions when ambiguous data arrive. The advanced FOXO4-DRI user is also in a position to contribute to the broader knowledge base about research peptide use. Sharing anonymized personal data on forums, contributing to citizen science projects, or participating in structured n=1 experiments with careful design can provide information that informs other users' decisions. This is not a substitute for clinical trials, but it is better than the current anecdote-based information environment for research peptides. Advanced users should also consider protocol exit. Longevity interventions do not need to be continued indefinitely; if markers are optimized and lifestyle is supporting health, pharmacologic intervention can be scaled back. Planned de-escalation — removing the lowest-value compounds first, then progressively simplifying the stack — is a rational strategy. The goal of longevity is long-term health, not maximum peptide stacking complexity. The discipline of stopping is part of responsible self-experimentation. Advanced users also bear responsibility for informed consent from any partners, family, or dependents who may be affected by their health choices. Research-chemical protocols carry non-trivial risks, and transparent communication with people whose lives are connected to yours is part of ethical self-experimentation. The advanced FOXO4-DRI protocol is the most sophisticated available approach to senolytic self-experimentation, but it remains fundamentally uncontrolled, unvalidated, and subject to the same uncertainties as the beginner protocol. The additional complexity does not compensate for the absence of clinical trial data.
Commonly Stacked With
FOXO4-DRI's senolytic mechanism places it in a distinctive position in the longevity-intervention landscape. Senolytic therapy is not meant to be chronic — the premise is that senescent cells accumulate over time and can be periodically removed, after which the benefit persists until senescent cells re-accumulate, which may take months to years. This episodic dosing model is different from most other longevity compounds (NAD+ precursors, GH secretagogues, anti-inflammatory peptides) that are dosed daily or continuously. Stacking FOXO4-DRI therefore means coordinating an episodic pulse of senolytic activity with ongoing baseline interventions, rather than adding a third or fourth daily compound. With other senolytics the combination concept is worth addressing because senescent cell populations are heterogeneous, and different senolytics have different selectivity profiles. The dasatinib-quercetin combination, fisetin, ABT-263 (navitoclax), and FOXO4-DRI all have senolytic activity but through different mechanisms and with different cell-type specificity. In principle, combining senolytics or cycling through them might address heterogeneity in senescent cell populations more effectively than any single agent. In practice, the evidence for this combination approach is absent in humans and limited in preclinical work. The most common real-world stacking pattern involves using fisetin (typically 20 mg/kg for 2-3 consecutive days monthly or quarterly) as a widely available oral senolytic, with occasional FOXO4-DRI pulses for users who have specific interest in FOXO4-p53 targeting. Dasatinib-quercetin requires a prescription for dasatinib and is used by some users under physician supervision. The combination of multiple senolytics on the same day compounds unknown risks and is not recommended. With NAD+ precursors and sirtuin activators — NAD+, NR, NMN, resveratrol, pterostilbene — the mechanistic rationale is that senolytic clearance of damaged cells followed by sustained NAD+/sirtuin support of healthy cells represents a reasonable two-stage longevity strategy. These compounds are typically continued through senolytic cycles without adjustment. With mitochondrial support — L-Carnitine, coenzyme Q10, PQQ, alpha-lipoic acid — continuous use during and between senolytic cycles is reasonable because mitochondrial support and senolytic clearance address different aspects of cellular aging. With 5-Amino-1MQ for NNMT inhibition, continuous use alongside pulsed senolytic dosing is not contraindicated on mechanistic grounds, though the combination is entirely unstudied. With Methylene Blue, Humanin, Epithalon, Thymosin Alpha-1, and other longevity peptides — continuous use alongside periodic FOXO4-DRI dosing is the default pattern in comprehensive biohacker stacks, with no clinical evidence establishing that specific combinations produce better outcomes than any single intervention. With tissue-repair peptides — BPC-157, TB-500, GHK-Cu, KPV — the interaction is mechanistically interesting because senescent cells play roles in both tissue repair (transient positive contribution) and chronic tissue dysfunction (sustained negative contribution). Combining senolytics with tissue-repair peptides could either complement each other (remove damaging senescent cells while supporting healthy tissue repair) or interfere (remove acute-phase senescent cells that are contributing to repair). Practical timing might involve using senolytics during quiescent periods and tissue-repair peptides during active injury recovery. With GH secretagogues — CJC-1295, Ipamorelin, Sermorelin, MK-677 — continuous use alongside senolytic dosing is common and without obvious mechanistic conflict, though IGF-1 elevation from GH axis activation has theoretical implications for cancer risk that interact with senolytic effects in complex ways. Users with cancer risk factors should consider this combination carefully with oncology input. With GLP-1 receptor agonists — Semaglutide, Tirzepatide, Retatrutide — continuous GLP-1 therapy alongside periodic senolytic dosing is common in multi-intervention metabolic health protocols. Senolytic effects on insulin-producing beta cells are of interest because beta cell senescence contributes to type 2 diabetes; senolytic clearance has been proposed as beneficial for beta cell function, which could theoretically interact with GLP-1 therapy. These interactions are speculative and unstudied in humans. With resistance training, cardiovascular training, and caloric restriction — the lifestyle interventions that reduce senescent cell accumulation independently — regular exercise and caloric discipline do not need to be adjusted around senolytic dosing. Training during immediate post-dose recovery (first 24-48 hours) is typically reduced because of fatigue or flu-like symptoms some users report, but routine training resumes thereafter. With NSAIDs and other anti-inflammatory agents — aspirin, ibuprofen, celecoxib — there is no clear mechanistic conflict with senolytic therapy, but the anti-inflammatory effects may mask any flu-like response to senolytic dosing that would otherwise be informative about the magnitude of senescent cell clearance. With cancer therapies — active chemotherapy, radiation, targeted therapy, immunotherapy — FOXO4-DRI should not be used during active cancer treatment without explicit oncology guidance. Senolytic interactions with cancer therapy are complex and potentially dangerous; chemotherapy induces widespread cellular senescence as part of its mechanism, and senolytic clearance could interact unpredictably with this process. The overall framework for stacking is that FOXO4-DRI is used pulsatilely (typically 2-5 consecutive days, 1-4 times per year) within a broader protocol of continuous longevity interventions, and the combinations have not been clinically validated but do not have obvious safety conflicts on mechanistic grounds at reasonable doses.
Side Effects & Safety
Contraindications
FOXO4-DRI's senolytic mechanism creates a specific contraindication profile reflecting concerns about cancer, reproduction, acute illness, and drug interactions. Active malignancy is a complex contraindication. On one hand, senescent cells in the tumor microenvironment can promote tumor progression through SASP effects, suggesting senolytic clearance might be beneficial. On the other hand, some cancer cells use senescence as a transient survival strategy during chemotherapy, and senolytic clearance could potentially interact unpredictably with cancer treatment. FOXO4-DRI should not be used during active cancer treatment without explicit oncology supervision within a research protocol. Patients with a history of cancer under surveillance should also avoid FOXO4-DRI outside of clinical trial participation because effects on dormant disease and surveillance are unknown. Recent cancer treatment (within 12 months of completion) warrants oncologist consultation even if surveillance is unremarkable. Pregnancy and breastfeeding are absolute contraindications. Senescent cells play specific roles in embryonic development, placental function, and neonatal physiology, and systemic senolytic therapy during pregnancy or lactation could disrupt these processes with potentially serious consequences. Anyone trying to conceive should avoid FOXO4-DRI because effects on gametogenesis, fertility, and early embryonic development are uncharacterized. Children and adolescents should not use FOXO4-DRI because cellular senescence plays normal roles in growth, development, and tissue remodeling during this life stage. Active acute infection is a relative contraindication because the senolytic mechanism may interact with immune responses to infection. Senescent immune cells can contribute to chronic inflammation but may also provide protective functions during acute infection. FOXO4-DRI dosing during active infection is not advised; waiting for infection resolution before initiating a senolytic cycle is prudent. Recent major surgery or injury is a relative contraindication because senescent cells play transient positive roles in acute wound healing and tissue repair. Senolytic dosing during active recovery from significant injury could theoretically impair healing. A general guideline is to avoid senolytic dosing for at least 4-6 weeks after major surgery or significant injury; consult with a physician for specific timing. Organ transplant recipients on immunosuppression are at increased risk with any immunomodulatory intervention, and FOXO4-DRI effects on immune cell senescence and transplant rejection are completely uncharacterized. Avoid in this population. Autoimmune disease on immunomodulatory therapy is a relative contraindication because effects on immune cell populations (which include senescent cells) and inflammatory signaling are not characterized. Patients with active rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, psoriasis, or other autoimmune conditions should discuss FOXO4-DRI with their treating specialist before use. Significant cardiovascular disease is a relative contraindication because effects on cardiac and vascular tissue senescence are not well characterized in humans, and the response of impaired cardiovascular systems to senolytic dosing is unknown. Stable cardiovascular disease with good medical management may be compatible with cautious senolytic dosing under physician supervision; unstable disease is not. Significant hepatic or renal impairment warrants caution because peptide clearance pathways are not characterized in these settings, and altered pharmacokinetics could produce higher-than-intended exposure. Patients with significant hepatic or renal disease should consult their physician before use. Uncontrolled diabetes is a relative contraindication because senescent beta cells contribute to type 2 diabetes pathogenesis, and senolytic effects on beta cell function could theoretically alter glucose homeostasis in unpredictable ways. Patients with well-controlled diabetes on stable regimens may be able to use FOXO4-DRI with monitoring; unstable glycemia is not the right context for adding uncharacterized compounds. Bleeding disorders or anticoagulant therapy are not absolute contraindications for subcutaneous injection, but the risk of injection-site bruising or hematoma is elevated and warrants attention. Patients on warfarin, direct oral anticoagulants, or antiplatelet therapy should apply pressure after injection and watch for persistent bleeding. Known hypersensitivity to peptide products or to any component of the preparation (including bacteriostatic water preservative) is an absolute contraindication. Medications with potential interactions are largely uncharacterized because no drug-drug interaction studies exist. Theoretical interactions include: chemotherapy agents (as discussed above); corticosteroids (senescent cell effects on corticosteroid responsiveness); immunosuppressants; anti-apoptotic drugs (navitoclax, venetoclax); mTOR inhibitors (rapamycin/sirolimus — mechanistic overlap with senolytic effects); metformin (reported senolytic activity in some contexts); other senolytic agents (dasatinib, fisetin — see stacking discussion); and any drug with narrow therapeutic window that might be affected by altered cellular composition in clearance tissues. Patients on any complex medication regimen should discuss FOXO4-DRI with their physician and pharmacist before use. The final and most important contraindication is the absence of clinical oversight. Self-experimentation with an unvalidated research peptide without a knowledgeable physician who can monitor response, order appropriate labs, and evaluate adverse events does not meet the minimum safety standard for a compound with FOXO4-DRI's risk profile. This is not a specific medical contraindication — it is an infrastructure contraindication that applies regardless of personal health status. Finding a physician with expertise in senolytic therapy is difficult but possible; the effort to establish this clinical relationship before starting is worth more than the peptide itself.
Additional Notes
FOXO4-DRI dosing for self-experimenters is extrapolated from rodent studies and self-report community patterns rather than validated clinical data. Typical dose ranges described in the protocol sections — 2-5 mg per dose for beginners, 5-10 mg for intermediate users, 10-15 mg for advanced users — are based on scaling from mouse studies using body surface area conversions and on vendor recommendations, neither of which has clinical validation. The most commonly reported single dose from self-report communities is 5 mg administered subcutaneously once daily. Cycle structure is pulsed rather than continuous: 3-7 consecutive days of dosing, followed by 2-6 months without dosing. The pulsed pattern is based on the concept that senescent cells require episodic clearance rather than continuous suppression, and it avoids the cumulative exposure concerns that would accompany continuous dosing of an unvalidated peptide. Total annual cycles range from 1-4 in typical protocols, based on personal response and risk tolerance. The theoretical basis for cycle frequency is that senescent cell burden accumulates over time and re-accumulates after clearance, with timescales in animal models suggesting months to a year for significant re-accumulation. Whether this timescale translates to humans is unknown, and conservative dosing schedules (less frequent cycles) are probably prudent in the absence of clinical data. Route of administration is overwhelmingly subcutaneous for self-experimenters, using insulin syringes (28-31 gauge) into abdominal fat, thigh, or upper arm. Subcutaneous injection is the safest route for self-administration, provides reasonable bioavailability for small peptides, and does not carry the acute risks of intravenous access. Intravenous FOXO4-DRI has been reported by some users, based on the rationale that IV delivery produces higher peak concentrations and more rapid tissue distribution, but IV self-administration carries significant risks (infection, vascular injury, acute reactions from bolus delivery) and is not appropriate outside of clinical supervision. Oral FOXO4-DRI would not be expected to work because the peptide would be degraded in the gastrointestinal tract despite its D-amino acid composition (the carriers and linkers may still be vulnerable to acid hydrolysis and gut enzymes), and oral absorption of a 34-amino-acid peptide would be poor regardless. Timing of administration within a cycle typically involves morning injections, though there is no pharmacokinetic basis for specific timing. Separating doses by roughly 24 hours is the standard pattern. Some users split cycles into "intense" patterns (5-7 consecutive daily doses) versus "pulsed" patterns (every-other-day dosing over 10 days). No clinical data support one pattern over another. Human pharmacokinetics of FOXO4-DRI are not published. The D-retro-inverso construction provides substantial protease resistance, extending plasma half-life relative to L-peptides of similar size, but exact half-life in humans is not characterized. Tissue distribution is assumed based on peptide properties (moderate lipophilicity, size appropriate for extravasation into many tissues) but not directly measured. Clearance pathways are not established. These PK gaps are part of why FOXO4-DRI dosing remains empirical rather than principle-based. Body weight adjustments are typically not made in self-administered protocols — a 60 kg person and a 100 kg person would typically use similar absolute doses — which is a feature of the research-chemical space rather than a defensible clinical approach. If scaling were done, it would be approximately 0.05-0.15 mg/kg per dose, which maps to the typical adult dose ranges. Missed doses within a cycle can be incorporated or skipped depending on user preference; a single missed day in a 5-day cycle is unlikely to substantially alter the biological effect. If a cycle is interrupted by illness or unexpected circumstances, restarting from the beginning of the cycle is reasonable but not clinically necessary. Overdose risk appears low based on the mechanism — senolytic clearance is self-limiting at the level of available senescent cells — but acute adverse effects from large bolus doses (injection site reactions, acute hypersensitivity, hypothetical acute inflammatory response from rapid senescent cell lysis) could theoretically occur. There is no specific antidote; supportive care is the approach. Quality of the peptide supply is the most variable element of the protocol. Research-peptide vendors vary significantly in purity, content accuracy, and manufacturing standards. Key vendor quality signals: published third-party analytical testing (HPLC or LC-MS identity and purity); reasonable prices within the market range (dramatically lower prices suggest adulteration); verified business presence with physical address and customer service; positive community reputation across multiple independent sources; and willingness to provide certificates of analysis on request. Vendors meeting these criteria are not necessarily pharmaceutical-grade, but they are substantially better than anonymous low-cost sources. Peptide content and purity below 95% warrants skepticism about the specific batch even from otherwise reliable vendors. Storage before reconstitution should be in the freezer in the original vial, sealed against humidity. Lyophilized peptide is generally stable for 1-2 years frozen, several months refrigerated, weeks at room temperature. After reconstitution with bacteriostatic water, the peptide should be refrigerated and used within 2-4 weeks. Signs of degradation (cloudiness, color changes, visible particulates) warrant discarding the vial.
Where to Buy FOXO4-DRI
Compare 4 listings across 3 vendors — from $59.99
Frequently Asked Questions
What is the recommended FOXO4-DRI dosage?
The typical dose range for FOXO4-DRI is 5 mg/kg IV infusion (research protocol, highly experimental). Always start with the lowest effective dose.
How often should I take FOXO4-DRI?
Administration frequency depends on the specific protocol. Consult current research literature.
Does FOXO4-DRI need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are FOXO4-DRI side effects?
The side effect profile of FOXO4-DRI in humans is not documented because no clinical trials have been conducted. Rodent studies from the Baar et al. 2017 publication and subsequent work report generally acceptable tolerability at doses producing senolytic activity, without overt signs of toxicity such as weight loss, abnormal behavior, or gross histopathologic changes in non-target tissues ([Baar et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28340339/)). The rodent tolerability picture is reassuring but limited: the studies were relatively short-duration (weeks to a few months), the dose ranges were specific to mouse weight and pharmacokinetics, and adverse effects at lower frequency or longer time horizons were not captured. Theoretical side effect concerns based on the senolytic mechanism include: effects on cancer risk, which is the most significant theoretical concern. Cellular senescence evolved in part as a tumor-suppressor mechanism — cells that accumulate DNA damage and oncogenic mutations enter senescence rather than proliferating, limiting cancer risk. Pharmacologic elimination of senescent cells could theoretically reduce this tumor-suppressor barrier and allow transformed cells that would have remained senescent to progress to cancer, particularly in older individuals who have accumulated somatic mutations. The counterargument is that senescent cells contribute to tumor progression through SASP-mediated effects on the tumor microenvironment, so removing them may reduce rather than increase cancer risk in some contexts. Both effects are plausible, and the net outcome for cancer risk in humans using chronic senolytic therapy is unknown. Tissue repair and wound healing effects: senescent cells play a transient positive role in acute wound healing and tissue regeneration, recruiting immune cells and producing growth factors that support repair. Eliminating senescent cells systemically could theoretically impair acute wound healing, though senolytic dosing can be timed to avoid periods of active injury. Effects on immune function: the immune system normally clears senescent cells to some extent, and pharmacologic senolysis works in parallel with this endogenous mechanism. Effects on immune cell populations (which can themselves undergo senescence) are not fully characterized. Effects on developmental biology: senescent cells play roles in normal embryonic development, limb morphogenesis, and placental function, making senolytic therapy contraindicated during pregnancy and development. Effects on specific tissues: kidney, liver, heart, brain, and reproductive tissues may respond differently to senolytic dosing, and tissue-specific effects have not been systematically characterized in humans. Injection-related effects: FOXO4-DRI is typically administered subcutaneously or intravenously as a research peptide, and injection site reactions (redness, swelling, discomfort) are common with subcutaneous peptide administration. Intravenous administration carries the additional risks of IV access complications (infection, vascular injury) that are not typically incurred with oral or SC peptides. Acute hypersensitivity reactions: any exogenous peptide can theoretically produce hypersensitivity or allergic responses, ranging from local urticaria to systemic anaphylaxis. FOXO4-DRI is a 34-amino-acid peptide with D-amino acid composition, which may reduce immunogenicity compared to L-amino acid peptides but does not eliminate it. Acute systemic effects: senolytic dosing that produces significant senescent cell death in a short window could theoretically produce acute effects from the released cellular contents (cytokines, damaged proteins, cellular debris), sometimes called a "senolytic tumor lysis" syndrome by analogy to chemotherapy tumor lysis. Whether this occurs clinically with FOXO4-DRI at typical doses is unknown; the dose-dependent pharmacology of senolysis in humans has not been established. Self-report data from the biohacker community using research-chemical FOXO4-DRI describe a range of experiences: some users report flu-like symptoms (fatigue, mild fever, joint aches) in the 24-72 hours following a dose, which has been interpreted as a senescent-cell-clearance response but could equally reflect pyrogen contamination in research-chemical supply, injection reactions, or nonspecific effects. Other users report no subjective effects. Others report subjective improvements in energy and appearance that may reflect placebo, other concurrent interventions, or specific biological responses. These reports are unverified, uncontrolled, confounded, and not generalizable. The absence of systematic safety data is the single most important feature of FOXO4-DRI for any prospective user to understand: the peptide has promising preclinical data, an elegant mechanism, and zero clinical validation. Anyone proceeding with self-administration is taking on both the pharmacologic risks of an unvalidated biological intervention and the supply-chain risks of research-chemical sourcing.
Where can I buy FOXO4-DRI?
Compare 4 listings from 3 vendors on our price comparison page — starting from $59.99.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.